DANTE Study: The First Randomized, Double-Blind, Placebo and Active-Controlled, Parallel Arm Group Study Evaluating the Analgesic Efficacy and Safety of Dexketoprofen TrometAmol aNd Tramadol Hydrochloride Oral FixEd Dose Combination on Moderate to Severe Acute Pain in Patients with Acute Low Back Pain-Rationale and Design.
Acute pain
Dexketoprofen
Low back pain
Radiculopathy
Tramadol
Journal
Pain and therapy
ISSN: 2193-8237
Titre abrégé: Pain Ther
Pays: New Zealand
ID NLM: 101634491
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
23
03
2022
accepted:
14
06
2022
pubmed:
6
7
2022
medline:
6
7
2022
entrez:
5
7
2022
Statut:
ppublish
Résumé
Despite a wide range of treatment approaches and the availability of treatment recommendations or guidelines, no consensus on the most effective pharmacological therapy of low back pain (LBP) has been reached yet. Therefore, additional clinical evidence, particularly if built upon a rigorous clinical trial design, an evidence-based medication choice, and broader inclusion criteria better acknowledging the heterogeneity and intrinsic variability of LBP is needed. The DANTE study has been designed to comprehensively assess the analgesic efficacy and tolerability of dexketoprofen/tramadol (DKP/TRAM) 75/25 mg in a large cohort of patients with moderate to severe acute LBP. The DANTE study is a phase IV, multicenter, randomized, double-blind, double-dummy parallel group, placebo, and active controlled study. The DANTE study encompasses a single-dose phase (day 1, t0-t8h) and a multiple-dose phase (from t8h to 8 h after intake of last dose at day 5). The DANTE study population includes patients naïve to LBP or patients with previous history of LBP experiencing a new episode of moderate to severe intensity with or without radiculopathy. The clinical phase of the DANTE study started in September 2020 and the anticipated completion date is April 2022. The primary endpoint is the time to first achieve a numeric rating scale-pain intensity (NRS-PI) score of < 4 or a pain intensity reduction ≥ 30% from drug intake up to 8 h after the first dose (t8h). Secondary objectives aim are: (1) to evaluate the analgesic efficacy of TRAM/DKP 75/25 mg versus TRAM 100 mg after the first dose; (2) to evaluate the analgesic efficacy of TRAM/DKP 75/25 mg versus TRAM 100 mg after the multiple doses (from t8h until day 5, multiple dose); and (3) to assess the safety and tolerability of the TRAM/DKP 75/25 mg fixed combination after single and multiple doses. EudraCT number: 2019-003656-37.
Identifiants
pubmed: 35788976
doi: 10.1007/s40122-022-00407-8
pii: 10.1007/s40122-022-00407-8
pmc: PMC9314501
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1055-1070Informations de copyright
© 2022. The Author(s).
Références
Rubin DI. Epidemiology and risk factors for spine pain. Neurol Clin. 2007;25:353–71.
pubmed: 17445733
doi: 10.1016/j.ncl.2007.01.004
Alexander CE, Varacallo M. Lumbosacral radiculopathy. NCBI bookshelf. A service of the National Library of Medicine, National Institutes of Health. https://www.ncbi.nlm.nih.gov/books/NBK430837/?report=printable . Accessed 7 Apr 2021.
Wu A, March L, Zheng X, et al. Global low back pain prevalence and years lived with disability from 1990 to 2017: estimates from the Global Burden of Disease Study 2017. Ann Transl Med. 2020;8:299.
pubmed: 32355743
pmcid: 7186678
doi: 10.21037/atm.2020.02.175
Grabovac I, Dorner TE. Association between low back pain and various everyday performances. Wien Klin Wochenschr. 2019;131:541–9.
pubmed: 31493101
pmcid: 6851039
doi: 10.1007/s00508-019-01542-7
Hartvigsen J, Hancock MJ, Kongsted A, et al. What low back pain is and why we need to pay attention. Lancet. 2018;10137:2356–67.
doi: 10.1016/S0140-6736(18)30480-X
Oliveira CB, Maher CG, Pinto RZ, et al. Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. Eur Spine J. 2018;27:2791–803.
pubmed: 29971708
doi: 10.1007/s00586-018-5673-2
Hooten WM, Cohen SP. Evaluation and treatment of low back pain: a clinically focused review for primary care specialists. Mayo Clin Proc. 2015;90:1699–718.
pubmed: 26653300
doi: 10.1016/j.mayocp.2015.10.009
Selim AJ, Ren XS, Fincke G, et al. The importance of radiating leg pain in assessing health outcomes among patients with low back pain. Results from the Veterans Health Study. Spine (Phila Pa 1976) 1998;23:470–74.
Parker SL, Godil SS, Mendenhall SK, et al. Two-year comprehensive medical management of degenerative lumbar spine disease (lumbar spondylolisthesis, stenosis, or disc herniation): a value analysis of cost, pain, disability, and quality of life. J Neurosurg Spine. 2014;21:143–9.
pubmed: 24785973
doi: 10.3171/2014.3.SPINE1320
Maher C, Underwood M, Buchbinder R. Non-specific low back pain. Lancet. 2017;389:736–47.
pubmed: 27745712
doi: 10.1016/S0140-6736(16)30970-9
Nguyen C, Lefèvre-Colau M, Kennedy DJ, Schneider BJ, Rannou F. Low back pain. Lancet. 2018;392:2547.
pubmed: 30563633
doi: 10.1016/S0140-6736(18)32187-1
Allegri M, Montella S, Salici F, et al. Mechanism of low back pain: a guide for diagnosis and therapy. F1000Research. 2016; 5(F1000 Faculty Rev):1530.
da Silva T, Mills K, Brown BT, et al. Risk of recurrence of low back pain: a systematic review. J Orthop Sports Phys Ther. 2017;47:305–13.
pubmed: 28355981
doi: 10.2519/jospt.2017.7415
Itz CJ, Geurts JW, van Kleef M, Nelemans P. Clinical course of non-specific low back pain: a systematic review of prospective cohort studies set in primary care. Eur J Pain. 2013;17(1):5–15.
pubmed: 22641374
doi: 10.1002/j.1532-2149.2012.00170.x
Migliorini F, Maffulli N, Eschweiler J, et al. The pharmacological management of chronic lower back pain. Expert Opin Pharmacother. 2021;22(1):109–19.
pubmed: 32885995
doi: 10.1080/14656566.2020.1817384
Morlion B. Pharmacotherapy of low back pain: targeting nociceptive and neuropathic pain components. CMRO. 2011;27:11–33.
Qaseem A, Wilt T, McLean RM, et al. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166:514–30.
pubmed: 28192789
doi: 10.7326/M16-2367
O’Connell NE, Chook CE, Wand BM, Ward SP. Clinical guidelines for low back pain: a critical review of consensus and inconsistencies across three major guidelines. Best Pract Res Clin Rheumatol. 2016;30:968–80.
pubmed: 29103554
doi: 10.1016/j.berh.2017.05.001
Di Iorio D, Henley E, Doughty A. A survey of primary care physician practice patterns and adherence to acute low back problem guidelines. Arch Fam Med. 2000;9:1015–21.
pubmed: 11115201
doi: 10.1001/archfami.9.10.1015
Schers H, Braspenning J, Drijver R, Wensing M, Grol R. Low back pain in general practice: reported management and reasons for not adhering to the guidelines in The Netherlands. Br J Gen Pract. 2000;50:640–4.
pubmed: 11042916
pmcid: 1313775
Ivanova J, Birnbaum HG, Schiller M, Kantor E, Johnstone BM, Swindle RW. Real-world practice patterns, health-care utilization, and costs in patients with low back pain: the long road to guideline-concordant care. Spine J. 2011;11:622–32.
pubmed: 21601533
doi: 10.1016/j.spinee.2011.03.017
Amonkar SJ, Dunbar AM. Do patients and general practitioners have different perceptions about the management of simple mechanical back pain? Int Musculoskelet Med. 2011;33:3–7.
doi: 10.1179/175361511X12972993698186
Ramanathan SA, Hibbert PD, Maher CG, et al. CareTrack: toward appropriate care for low back pain. Spine (Phila Pa 1976). 2017;42:E802–9.
Varrassi G, Moretti B, Pace MC, Evangelista P, Iolascon G. Common clinical practice from low back pain treatment: a modified Delphi study. Pain Ther. 2021;10:589–604.
pubmed: 33713307
pmcid: 8119580
doi: 10.1007/s40122-021-00249-w
Enke O, New HA, New CH, et al. Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis. CMAJ. 2018;190:E786-93.
pubmed: 29970367
pmcid: 6028270
doi: 10.1503/cmaj.171333
Ferreira GE, MacLachlan AJ, Chung-Wei CL, et al. Efficacy and safety of antidepressants for the treatment of back pain and osteoarthritis: systematic review and meta-analysis. BMJ. 2021;372:n80.
Varrassi G, Alon E, Bagnasco M, Lanata L, Mayoral- Rojals V, Paladini A, et al. Towards an effective and safe treatment of inflammatory pain: a Delphi-guided expert consensus. Adv Ther. 2019;36:2618–37.
pubmed: 31485978
pmcid: 6822819
doi: 10.1007/s12325-019-01053-x
Williams CM, Maher CG, Latimer J, et al. Efficacy of paracetamol for acute low-back pain: a double-blind, randomised controlled trial. Lancet. 2014;384: 961586.
doi: 10.1016/S0140-6736(14)60805-9
Roelofs PD, Deyo RA, Koes BW, et al. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev. 2008;23:CD000396.
Shaheed CA, Ferreira G, Dmitritchenko A, et al. The efficacy and safety of paracetamol for pain relief: an overview of systematic reviews. Med J Aust. 2021;214:324–31.
pubmed: 33786837
doi: 10.5694/mja2.50992
Saragiotto BT, Machado GC, Ferreira ML, Pinheiro MB, Abdel Shaheed C, Maher CG. Paracetamol for low back pain. Cochrane Database System Rev. 2016(6):CD012230.
Babej DR, Freytag S, Eckmeyer J, et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer blind multicenter study. Int J Clin Pharmacol Ther. 1994;32:204–9.
Amlie E, Weber H, Holme I. Treatment of acute low-back pain with piroxicam: results of a double-blind placebo-controlled trial. Spine (Phila Pa 1976). 1987;12:473–6.
Friedman BW, Dym AA, Davitt M, et al. Naproxen with cyclobenzaprine, oxycodone/acetaminophen, or placebo for treating acute low back pain: a randomized clinical trial. JAMA. 2015;314:1572–80.
pubmed: 26501533
doi: 10.1001/jama.2015.13043
Varrassi G, Hanna M, Macheras G, et al. Multimodal analgesia in moderate-to-severe pain: a role for a new fixed combination of dexketoprofen and tramadol. Curr Med Res Opin. 2017;33:1165–73.
pubmed: 28326850
doi: 10.1080/03007995.2017.1310092
Hanna M, Montero A, Perrot S, Varrassi G. Tramadol/dexketoprofen analgesic efficacy compared with tramadol/paracetamol in moderate to severe postoperative acute pain: subgroup analysis of a randomized, double-blind, parallel group trial—DAVID study. Pain Ther. 2021;10:485–503.
pubmed: 33575951
pmcid: 8119575
doi: 10.1007/s40122-020-00228-7
Mathieson S, Kasch R, Maher CG, et al. Combination drug therapy for the management of low back pain and sciatica; systematic review and meta-analysis. J Pain. 2019;20:1–15.
pubmed: 30585164
doi: 10.1016/j.jpain.2018.06.005
Varrassi G, Yeam CT, Rekatsina M, Pergolizzi JV, Zis P, Paladini A. The expanding role of the COX inhibitor/opioid receptor agonist combination in the management of pain. Drugs. 2020;80:1443–53.
pubmed: 32749653
pmcid: 7401469
doi: 10.1007/s40265-020-01369-x
Moore RA, Gay-Escoda C, Figueiredo R, et al. Dexketoprofen/tramadol: randomised double-blind trial and confirmation of empirical theory of combination analgesics in acute pain. J Headache Pain. 2015;16:541.
pubmed: 26123824
doi: 10.1186/s10194-015-0541-5
Moore RA, McQuay HJ, Tomaszewski J, et al. Dexketoprofen/tramadol 25 mg/75 mg: randomised double-blind trial in moderate-to-severe acute pain after abdominal hysterectomy. BMC Anesthesiol. 2016;16:9.
pubmed: 26801905
pmcid: 4724087
doi: 10.1186/s12871-016-0174-5
McQuay HJ, Moore RA, Berta A, et al. Randomized clinical trial of dexketoprofen/tramadol 25mg/75mg in moderate-to-severe pain after total hip arthroplasty. Br J Anaesth. 2016;116:269–76.
pubmed: 26787797
pmcid: 4718147
doi: 10.1093/bja/aev457
Gay-Escoda C, Hanna M, Montero A, et al. Tramadol/dexketoprofen (TRAM/DKP) compared with tramadol/paracetamol in moderate to severe acute pain: results of a randomised, double-blind, placebo and active-controlled, parallel group trial in the impacted third molar extraction pain model (DAVID study). BMJ Open. 2019;9:e023715.
pubmed: 30782886
pmcid: 6377526
doi: 10.1136/bmjopen-2018-023715
Montero Matamala A, Bertolotti M, Contini MP, et al. Tramadol hydrochloride 75 mg/dexketoprofen 25 mg oral fixed-dose combination in moderate-to-severe acute pain: sustained analgesic effect over a 56-h period in the postoperative setting. Drugs Today (Barc). 2017;53:339–47.
doi: 10.1358/dot.2017.53.6.2636487
Meloncelli S, Divizia M, Germani G. Efficacy and tolerability of orally administered tramadol/dexketoprofen fixed- dose combination compared to diclofenac/thiocolchicoside in acute low back pain: experience from an Italian, single-centre, observational study. Curr Med Res Opin. 2020;36:1687–93.
pubmed: 32838578
doi: 10.1080/03007995.2020.1814228
Perna A, Ricciardi L, Barone G, et al. Medical management of acute non-specific low back pain: comparison of different medical treatments, one center’s retrospective analysis. J Biol Regul Homeost Agents. 2018;32:121–9.
pubmed: 30644292
Spitzer WO. Scientific approach to the assessment and measurement of activity-related spinal disorders: a monograph for clinicians—report of the Quebec Task Force on spinal disorders. Spine. 1987;12(Suppl):S1–59.
Roland MO, Morris RW. A study of the natural history of back pain. Part I: development of a reliable and sensitive measure of disability in low back pain. Spine 1983; 8:141–4.
Roland MO, Morris RW. A study of the natural history of back pain. Part II: development of guidelines for trials of treatment in primary care. Spine 1983;8: 145–50.
Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcome. 2004;2:1–13.
doi: 10.1186/1477-7525-2-1
Lasko B, Jevitt RJ, Rainsford KD, Bouchard S, Rozova A, Robertson S. Extended-release tramadol/paracetamol in moderate-to-severe pain: a randomized, placebo-controlled study in patients with acute low back pain. Curr Med Res Opin. 2021;28:847–57.
doi: 10.1185/03007995.2012.681035
European Medicines Agency. Guidance on clinical investigation of medicinal products for treatment of nociceptive pain (CPMP/EWP/612/00). https://www.ema.europa.eu/en/documents/scientific-guideline/noteguidance-clinical-investigation-medicinal-products-treatment-nociceptive-pain_en.pdf . Accessed 7 Apr 2021
European Medicines Agency. Guideline on clinical medicinal products intended for the treatment of neuropathic pain (CPMP/EWP/252/03). https://www.ema.europa.eu/en/documents/scientific-guideline/guidelineclinical-medicinal-products-intended-treatment-neuropathic-pain_en.pdf . Accessed 7 Apr 2021
Carvalho C, Caetano JM, Cunha L, et al. Open-label placebo treatment in chronic low back pain: a randomized controlled trial. Pain. 2016;157:2766–72.
pubmed: 27755279
pmcid: 5113234
doi: 10.1097/j.pain.0000000000000700
European Medicines Agency. Paracetamol tablets 500mg. Accord-UK Ltd. https://www.medicines.org.uk/emc/product/5916/smpc#gref . Accessed 7 Apr 2021.
Panella L, Rinonapoli G, Coaccioli S. Where should analgesia lead to? Quality of life and functional recovery with tapentadol. J Pain Res. 2019;12:1561–7.
pubmed: 31190967
pmcid: 6529727
doi: 10.2147/JPR.S190158
Van Boekel RLM, Vissers KCP, van der Sande R, Bronkhorst E, Lerou JGC, Steegers MAH, et al. Moving beyond pain scores: multidimensional pain assessment is essential for adequate pain management after surgery. PLoS One. 2017;12:e0177345.
pubmed: 28489926
pmcid: 5425226
doi: 10.1371/journal.pone.0177345
Deyo RA, Battie M, Beurskens AJ, et al. Outcome measures for low back pain research: a proposal for standardized use. Spine (Phila Pa 1976) 1998;23:2003–13.
Smeets R, Koke A, Lin CW, Ferreira M, Demoulin C. Measures of function in low back pain/disorders: Low Back Pain Rating Scale (LBPRS), Oswestry Disability Index (ODI), Progressive Isoinertial Lifting Evaluation (PILE), Quebec Back Pain Disability Scale (QBPDS), and Roland-Morris Disability Questionnaire (RDQ). Arthritis Care Res. 2011;63(Suppl S11):S158–73.
Turner JA, Fulton-Kehoe D, Franklin G, Wickizer TM, Wu R. Comparison of the Roland–Morris Disability Questionnaire and generic health status measures: a population-based study of workers' compensation back injury claimants. Spine (Phila Pa 1976). 2003;28810:1061–7.
Varrassi G, Coaccioli S, De-Andres J, et al. Expert consensus on clinical use of an orally administered dexketoprofen plus tramadol fixed- dose combination in moderate-to-severe acute pain: a Delphi study. Adv Ther. 2019;36:3174–85.
pubmed: 31535328
pmcid: 6822787
doi: 10.1007/s12325-019-01096-0